AIP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arteris Inc is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock just suffered a sharp 19.97% regular-session drop to 35.195, and while the long-term analyst tone is constructive, the current technical setup and lack of fresh catalysts make this a wait-and-see rather than an immediate buy. Since the user is unwilling to wait for an ideal entry, my direct view is still hold, not buy.
The price trend is mixed-to-weak in the short term. MACD histogram is -0.565 and still negatively expanding, which points to downside momentum. RSI_6 at 28.978 is near oversold but not giving a clean reversal signal. The moving averages are still structurally bullish with SMA_5 > SMA_20 > SMA_200, so the longer trend is not broken, but the day’s sharp drop from 43.81 to 35.195 and current price near support increases near-term risk. Key support is around 36.441 (S1), and price is already below it, which is a negative sign. The next support is 32.653. The stock trend model suggests a modest rebound potential over the next week/month, but not enough to justify an aggressive immediate buy after such a large decline.
Analysts are broadly constructive after a beat-and-raise quarter. Rosenblatt, Northland, and TD Cowen all raised targets to the $38-$40 range and maintained positive ratings, citing accelerating AI/data center demand and earlier royalty realization. The company is benefiting from data center and AI-related licensing momentum, which could improve revenue mix and royalty trends. The stock trend model also points to potential upside over the next month.
There has been no recent news in the past week, so there is no immediate event-driven catalyst supporting a fresh entry. Insiders are selling, and the selling amount increased 277.85% over the last month, which is a negative sentiment signal. Hedge funds are neutral. The stock also experienced a very sharp single-day decline, and technical momentum is currently weak. Jefferies remains only Hold, citing uncertainty around profitability after increased spending.
Latest quarter financials were not fully provided due to a financial snapshot error, but the available analyst commentary says Arteris reported a beat-and-raise quarter in Q1 and guided above consensus. Northland noted Q1 EPS ahead of consensus and stronger guidance, while TD Cowen said all metrics exceeded expectations. The latest quarter season appears to be Q1 FY26, and the main positive growth trend is improving demand from AI/datacenter licensing, which is driving faster royalty realization.
Analyst sentiment is positive overall, with multiple target raises in May 2026: Rosenblatt to $38 from $20 (Buy), Northland to $38 from $24 (Outperform), and TD Cowen to $40 from $22 (Buy). Jefferies also raised its target to $35 from $16 but kept Hold, showing some concern about profitability and spending. Overall Wall Street pros are constructive on growth and AI/data center exposure, but not unanimous on valuation and execution. There is no recent politician or congress trading activity, and no notable recent insider buying—only increased insider selling.
